

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

1) What's New

- A. In September of 2026, the West Coast Health Alliance (WCHA) issued immunization recommendations for the 2026-2027 respiratory virus season. These recommendations were informed by trusted national medical organizations, including the [American Academy of Pediatrics \(AAP\)](#), the [American College of Obstetricians and Gynecologists \(ACOG\)](#), and the [American Academy of Family Physicians \(AAFP\)](#). The WCHA believes that all recommended immunizations should be accessible to the people of our states and aims to ensure that public health recommendations are guided by safety, efficacy, transparency, access and trust.
- B. Individuals 7 years of age and older may receive the current COVID-19 vaccine (Moderna, Novavax, or Pfizer-BioNTech).

2) Immunization Protocol

- A. Administer one or more doses of the current COVID-19 vaccine based on level of immunocompetency, age, and previous vaccination status. Follow Section 3 for information regarding eligibility and dosing schedule.
- B. COVID-19 vaccine may be given with all ACIP- and WCHA-recommended adult vaccinations. There is no need to separate COVID-19 vaccine from other vaccinations by 2 weeks.

3) Vaccine Schedule

Age/Condition	COVID-19
Children ^A	• All 7 through 18 years with risk factors or never vaccinated against COVID-19 • All who are in close contact with others with risk factors • All who choose to reduce risk of severe illness
Pregnancy ^B	• All who are planning pregnancy, pregnant or postpartum
Adults ^C	• All 65 years and older • All 19 -64 years with risk factors • All who are in close contact with others with risk factors • All who choose to reduce risk of severe illness
Healthcare Workers	• All

^A For dosing details for children, including those who are moderately to severely immunocompromised, see the [AAP Recommended Child and Adolescent Immunization Schedule](#).

^B For dosing details for those who are planning pregnancy, pregnant or postpartum, see the [ACOG Maternal Immunization Schedule](#).

^C For dosing details for adults, including those who are moderately to severely immunocompromised, see the [AAFP Recommended Adult Immunization Schedule](#).

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

4) Additional Considerations for Use²

- B. Shared clinical decision-making:
 - i) Unlike routine, catch-up, and risk-based recommendations, shared clinical decision-making vaccinations are not recommended for everyone in a particular age group or everyone in an identifiable risk group. Rather, shared clinical decision-making recommendations are individually based and informed by a decision process between the health care provider and the patient or parent/guardian.
 - ii) For shared clinical decision-making recommendations, there is no default—the decision about whether or not to vaccinate may be informed by the best available evidence of who may benefit from vaccination; the individual’s characteristics, values, and preferences; the health care provider’s clinical discretion; and the characteristics of the vaccine being considered.
 - iii) Generally, ACIP makes shared clinical decision-making recommendations when individuals may benefit from vaccination, but broad vaccination of people in that group is unlikely to have population-level impacts.
 - iv) See link in Reference 2 for additional guidance.

5) Pregnancy and Lactation

- A. COVID-19 vaccination is recommended for all who are planning pregnancy, pregnant or postpartum.
- B. See current prescribing information for additional considerations regarding pregnancy and lactation.

6) Warnings and Precautions³

- A. History of severe allergic reaction (e.g., anaphylaxis) to any other vaccine or injectable therapy (e.g., intravenous, intramuscular or subcutaneous).
- B. Persons who have a contraindication to additional doses of mRNA COVID-19 vaccines are considered to have a precaution to the Novavax vaccine. A single dose may be given in an appropriate setting under the supervision of a health care provider experienced in the management of severe allergic reactions. Consider referral to an allergist-immunologist. This additional dose could be considered after a minimum interval of 28 days after the mRNA COVID-19 vaccine dose.
- C. Moderate or severe acute illness.
- D. Development of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine, and subsequent doses should generally be avoided.
- E. See current prescribing information for more details about warnings, precautions, formulation, and contents.

7) Contraindications

- A. Severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component.
- B. See current prescribing information for more details about contraindications.

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

8) Storage and Handling

- A. Store medications according to manufacturer's directions.
- B. See current prescribing information for more details about storage and handling.
- C. All clinics and pharmacies enrolled with the Vaccines for Children (VFC) Program must immediately report any storage and handling deviations to the Oregon Immunization Program at 971-673-4VFC (4823).

9) References

- 1. Consensus WCHA 2026-2027 Respiratory Virus Season Immunization Recommendations.
Available at:
<https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/VACCINESIMMUNIZATION/IMMUNIZATIONPROVIDERRESOURCES/Documents/WCHARespiratorySeasRecommendations.pdf>
- 2. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) Shared Clinical Decision-Making Recommendations. Available at:
<https://www.cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html>
- 3. Interim clinical considerations for use of COVID-19 vaccines in the United States, October 31, 2024. Available at: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>